Literature DB >> 9861619

An update of radiopharmaceutical schedules in children.

T Smith1, I Gordon.   

Abstract

Proposed radiopharmaceutical schedules based on readily measured parameters (age, height, weight, surface area) have been considered with respect to their applicability in nuclear medicine. Although schedules based on age are considered to be inappropriate, there are valid cases for schedules based on height, weight and surface area. For many radiopharmaceutical studies, the most appropriate schedules are based on weight or surface area. Examination of simple theoretical physical models, including the influence of attenuation, suggests that the optimum administered amounts of radiopharmaceuticals fall mainly within the region bounded by these two schedules. The results of recent clinical studies designed to test the validity of different schedules are summarized. In general, they support the predictions of theoretical models, but also show how simple models can be influenced significantly by the age dependency of radiopharmaceutical biodistribution. The schedule based on surface area (or height) is less likely than that based on weight to require the identification of minimum administered amounts of radiopharmaceutical to preserve image quality in small children. However, recent studies have shown that the most appropriate schedule for regional cerebral blood flow with 99Tcm-HMPAO is that based on weight, without the need for a minimum activity. Paediatric radiation dosimetry is briefly summarized to indicate some recent innovations in methodology. Effective doses per unit of administered radiopharmaceutical (mSv MBq-1) have been calculated using five paediatric phantoms for a number of radiopharmaceuticals commonly used in children. Values of total effective dose resulting from the application of the weight and surface area schedules are presented, based on the adult reference amounts of administered radiopharmaceutical proposed by the Paediatric Task Group of the European Association of Nuclear Medicine. Although some values of effective dose exceed 10 mSv for the surface area schedule, the majority of values are less than 5 mSv.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9861619     DOI: 10.1097/00006231-199811000-00002

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Guidelines for direct radionuclide cystography in children.

Authors:  Jure Fettich; Paula Colarinha; Sibylle Fischer; Jörgen Frökier; Isky Gordon; Klaus Hahn; Levent Kabasakal; Mike Mann; Mercedes Mitjavila; Pierre Olivier; Amy Piepsz; Ute Porn; Isabel Roca; Rune Sixt; Jeannette van Velzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

2.  Paediatric doses--a critical appraisal of the EANM paediatric dosage card.

Authors:  Søren Holm; Lise Borgwardt; Annika Loft; Jesper Graff; Ian Law; Liselotte Højgaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

3.  Guidelines for standard and diuretic renogram in children.

Authors:  Isky Gordon; Amy Piepsz; Rune Sixt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06       Impact factor: 9.236

4.  Comparison of differential renal function using technetium-99m mercaptoacetyltriglycine (MAG3) and technetium-99m dimercaptosuccinic acid (DMSA) renography in a paediatric population.

Authors:  Gillian Ritchie; Alistair G Wilkinson; Robin J Prescott
Journal:  Pediatr Radiol       Date:  2008-06-13

5.  Report of a nationwide survey on actual administered radioactivities of radiopharmaceuticals for diagnostic reference levels in Japan.

Authors:  Hiroshi Watanabe; Kazunari Ishii; Makoto Hosono; Etsuko Imabayashi; Koichiro Abe; Masayuki Inubushi; Kazuko Ohno; Yasuhiro Magata; Kinya Ono; Kei Kikuchi; Kei Wagatsuma; Tadashi Takase; Kyoko Saito; Yasuyuki Takahashi
Journal:  Ann Nucl Med       Date:  2016-05-06       Impact factor: 2.668

6.  Revised guidelines on management of antenatal hydronephrosis.

Authors:  A Sinha; A Bagga; A Krishna; M Bajpai; M Srinivas; R Uppal; I Agarwal
Journal:  Indian J Nephrol       Date:  2013-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.